News Breaks |
|
|
| November 28, 2012 |
| 13:39 EDT |  | CADX | Cadence settlement for Ofirmev a positive, says Deutsche Bank
Deutsche Bank views Cadence's (CADX) settlement with Perrigo (PRGO) regarding its pain management product Ofirmev as a very positive development since it could provide the company a longer than expected runway to fully benefit from Ofirmev’s projected cash flow. Deutsche now sees an increased likelihood that Cadence resolves Exela's patent challenge in the coming months and keeps a Buy rating on Cadence. |
|
|
News For CADX From The Last 14 Days Check below for free stories on CADX the last two weeks. |
|
|
| There are no results for CADX |
|
|
|
|
